$ORTX

Orchard Therapeutics plc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Major

PRICE

$0.6059 ▲0.464%

Extented Hours

VOLUME

255,850

DAY RANGE

0.5833 - 0.62

52 WEEK

0.412 - 3.18

Join Discuss about ORTX with like-minded investors

profile
@Navneet #droscrew
recently

$ortx 10 calls may

46 Replies 11 👍 15 🔥

profile
@Navneet #droscrew
recently

$ORTX #binaryevent #idea Data Tomorrow , Binary Events are very risky and can destroy account. That being said I am holding #long into data with @bioILLOGICAL See @bioILLOGICAL feed for #DD If you cant afford to lose, dnt play.

92 Replies 9 👍 10 🔥

profile
@dros #droscrew
recently

+Initiations 1/7: $ACCD $AIRC $ARAY $ARCT $AWK $BDTX $CHTR $CVLB $DADA $EVH $INCY $INOV $KNOP $MGTA $NOG $NTST $ORTX $TDOC $TLMD $VEEV . -Initiations 1/7: $FMCC

115 Replies 6 👍 11 🔥

profile
@sardic #StockTraders.NET
recently

long $ORTX

77 Replies 8 👍 12 🔥

Key Metrics

Market Cap

76.27 M

Beta

0.98

Avg. Volume

781.48 K

Shares Outstanding

126.46 M

Yield

0%

Public Float

0

Next Earnings Date

2022-11-03

Next Dividend Date

Company Information

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. The company's ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSK's rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Website:

HQ: 108 Cannon Street, EC4N 6EU London

Related News